Potential Anticancer Properties of Bisphosphonates
Authors:
- Helen L. Neville-WebbeHNHelen L. Neville-Webbe
- Michael GnantMichael Gnant
- Robert E. ColemanRCRobert E. Coleman
- 1 June 2010
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 37, S53-S65
Abstract
No abstract availableKeywords
Funding Information
- Novartis
This publication has 79 references indexed in Scilit:
- Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trialThe Lancet Oncology, 2010
- Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interactionBritish Journal of Cancer, 2010
- Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer riskBritish Journal of Cancer, 2010
- Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast CancerNew England Journal of Medicine, 2009
- Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow—a long-term follow-upAnnals of Oncology, 2008
- Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acidCancer, 2008
- Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancerBritish Journal of Cancer, 2007
- Meta-analysis of clodronate and breast cancer survivalBritish Journal of Cancer, 2007
- Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcomaBritish Journal of Cancer, 2007
- A Pooled Analysis of Bone Marrow Micrometastasis in Breast CancerNew England Journal of Medicine, 2005